<DOC>
	<DOC>NCT00237237</DOC>
	<brief_summary>Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.</brief_summary>
	<brief_title>Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>On a stable dose of metformin as defined by the protocol Blood glucose criteria must be met Body mass index (BMI) in the range 2245 History of type 1 diabetes Pregnancy or lactation Evidence of significant diabetic complications Serious cardiovascular events within the past 6 months Laboratory value abnormalities as defined by the protocol Known sensitivity to pioglitazone Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>